{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008723","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.978274+00:00","generated_at":"2026-05-15T22:17:59.190297+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies","bullets":["Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.","Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.","Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.","CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008723","json":"https://secwatch.observer/filing/0001493152-26-008723.json","markdown":"https://secwatch.observer/filing/0001493152-26-008723.md","text":"https://secwatch.observer/filing/0001493152-26-008723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/0001493152-26-008723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:17:59.190297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}